Long-term urokinase treatment in end-stage coronary artery disease;Konservative therapieansatze bei terminaler koronarer herzkrankheit. Chronisch-intermittierende urokinasetherapie

Herz

Volumn 22, Issue 5, 1997, Pages 262-271

  Leschke, M ^a   Schoebel, F C ^a   Jax, T W ^a   Schannwell, C M ^a   Marx, R ^a   Strauer, B E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Chronic thrombolysis; End stage CAD; Endothelial function; LDL cholesterol reduction; Thrombotic progression

Indexed keywords

UROKINASE;

ANGINA PECTORIS; CORONARY ARTERY DISEASE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; QUALITY OF LIFE; REVIEW; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DRUG ADMINISTRATION; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; LONG TERM CARE;

ANGINA PECTORIS; CORONARY CIRCULATION; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; HEMODYNAMIC PROCESSES; HUMANS; LONG-TERM CARE; THROMBOLYTIC THERAPY; URINARY PLASMINOGEN ACTIVATOR; VENTRICULAR FUNCTION, LEFT;

EID: 0031283191     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044254     Document Type: Review

References (51)

1. Anderson TJ, Meredith JT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent vasomotion. N Engl J Med 1995;332: 488-93.
2. Andrews TC, Raby K, Barry J, Naimi CL, Allred E,-Ganz P. Selwyn AP. Effect of the reduction of cholesterol-reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-8.
3. Benson, H, Mc Callie DP.: Angina pectoris and the placebo effect. N Engl J Med 1978;300:1424-9.
4. Beyer M. Kardiomyopexie - aktueller Stand eines indirekten Revaskularisationsverfahrens. Z Kardiol 1997;86:Suppl 1: 125-32.
5. Bini A, Fenoglia JJ, Mesa Tejeda R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis: use of monoclonal antibody. Atherosclerosis 1989;9:109-21.
6. Boven ADJ van, Jukema JW, Zwinderman AH, Crijns HJGM, Lie KL, Bruschke AVG, on behalf of the Regress Study Group. Reduction of transient myocardial ischemia in addition to the conventional treatment in patients with angina pectoris. Circulation 1996;94:1503-5.
7. Braunwald E, Jones RH, Mark DB, Brown J, Cheitlin MD, Concannas CA, Cohan M, Edwards C, Fuster V, Goldman L, Green LA, Grihes C, Lytle BW, Mc Cauley KM, Mushlin AI, Rose GC, Smith EE, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. Circulation 1994;90:613-22.
8. Broadhurst P, Kellher C, Hughes L. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990;85:169-73.
9. Campeau L. Grading of angina pectoris. Circulation 1976; 54:522-3.
10. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418-27.
11. de Jongste ML, Hautvast RWM, Hillege HL, Lie IL. Efficacy of spinal cord stimulation as adjuvant therapy for intractable angina pectoris: A prospective, randomized clinical study. J Am Coll Cardiol 1994;23:1592-7.
12. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium dependent coronary vasomotion in patients with hypercholesteroloemia. Circulation 1994;89: 2519-24.
13. Ehrly AM, Schenk JF. Systemisch niedrig dosierte Langzeit-Urokinasetherapie bei schwerster Angina pectoris. Grundlagen und erste Ergebnisse: In: Strauer BE, Ehrly AM, Leschke M, eds. Fortschritte in der kardiovaskulären Rheologie. München: Münchner Wissenschaftliche Publikationen, 1987:35-8.
14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
15. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in vascular occlusion. Circulation 1985; 71:699-708.
16. Fuster V, Badimon L, Badimon J, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). N Engl J Med 1992;326:242-50.
17. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992;326:310-8.
18. Gotto A. Lipid lowering, regression and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention. 7th council meeting. Circulation 1995; 92:646-56.
19. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation 1994;89:1530-8.
20. Horvath KA, Cohn LH, Cooley DA, Crew JR, Frazier OH, Griffith BP, Kadipasoglu K, Lansing A, Mannting F, March R, Mirhoseini MR, Smith C. Transmyocardial laser revascularization: results of a multi-center trial using TLR as a sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg 1997;113:645-53.
21. Kaiser GC, Davis KB, Fisher LD, Myers WO, Foster ED, Passamani ER, Gillespie MJ. Survival following coronary bypass grafting in patients with severe angina pectoris (CASS). J Thorac Cardiovasc Surg 1985;89:513-24.
22. Kaski JC, Chester MR, Chen L, Katritsis D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris - The role of complex lesion morphology. Circulation 1995;92:2058-65.
23. Kurz T, Rauch B, Kübler W. Antianginöse Therapie der koronaren Herzerkrankung. Mono- oder Kombinationsbehandlung. Z Kardiol 1991;80:305-16.
24. Leschke M, Blanke H, Stellwaag M, Motz W, Strauer BE. Hyperfibrinogenämie und pathologische Plasmaviskosität. Dtsch Med Wochenschr 1988;113:1175-81.
25. Leschke M, Höffken H, Motz W, Blanke H, Schoebel FC, Strauer BE. Chronisch intermittierende Urokinasetherapie bei therapierefraktärer Angina pectoris. Dtsch Med Wochenschr. 1992; 117:81-7.
26. Leschke M, Schoebel FC, Strauer BE. Symptomatische therapierefraktäre Myokardischamie bei koronarer Herzkrankheit. Internist (Berlin) 1996;37:597-606.
27. Leschke M, Schoebel FC, Mecklenbeck W, Stein D, Jax TW, Müller-Gärtner HW, Strauer BE. Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: A randomized dose-response trial. J Am Coll Cardiol 1996;27:575-84.
28. Leschke M, Schoebel FC, Heins M, Strauer BE. Antithrombotic treatment for the preservation and enhancement of myocardial perfusion in chronic coronary artery disease. Fibrinolysis and Proteolyis 1997;11:Suppl 1:119-23.
29. Leschke M, Schoebel FC, Schannwell CM, Peters AJ, Jax TW, Mecklenbeck W, Strauer BE. Chronisch intermittierende Urokinasetherapie: antiischämische und hämodynamische Effekte. Z Kardiol 1997;86:Suppl 1:85-94.
30. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-500.
31. Maisch B, Funck R, Schönian U, Moosdorf R. Indikation zur transmyokardialen Lasertherapie. Z Kardiol 1996;85:Suppl 6:269-79.
32. Mannheimer C, Augustinsson LE, Carlsson CA, Manhem K, Wilhelmsson C. Epiduralspinal electrical stimulation in severe angina pectoris. Br Heart J 1988;59:56-61.
33. Maseri A, Chierchia S, Kaski JC. Mixed angina pectoris. Am J Cardiol 1985;56:30E-3E.
34. Moosdorf R, Schoebel FC, Hort W. Transmyokardiale Laserrevaskularisation - morphologische, pathomorphologische und histologische Grundlagen der indirekten Revaskularisation des Herzmuskels. Z Kardiol 1997;86:149-64.
35. Nägele H, Kalmar P, Labeck M, Marcsek P, Nienhaber CA, Rödiger W, Stiel GM, Stubbe HM. Transmyokardiale Laserrevaskularisation - Behandlungsoption bei der koronaren Herzerkrankung? Z Kardiol 1997;86:171-8.
36. Nesto RW, Kowalchuk GJ The ischemic cascade: Temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol 1987;57:23C-30C.
37. Parker JD, Parker AB, Farell B, Parker JO. Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Circulation 1996;93:691-6.
38. Schmid-Schönbein H. Myokardiale Mikrozirkulation. Wechselwirkung zwischen Vasomotorik und Fließeigenschaften des Blutes. Dtsch Med Wochenschr 1981;106:1483.
39. Schneidau A, Harrison MJG, Hurst C, Wilkers HC, Meade TW. Arterial disease risk factors and angiographic evidence of atheroma of the carotid artery. Stroke 1989;20:1466-71.
40. Schoebel FC, Leschke M, Strauer BE. Therapierefraktäre Angina pectoris im Endstadium der koronaren Herzkrankheit - Pathophysiologische Grundlagen und alternative Therapieansatze. Dtsch Med Wochenschr 1995;120:301-307.
41. Schoebel FC, Leschke M, Heintzen MP, Strauer BE. Konservative Behandlungskonzepte für die stabile Angina pectoris bei koronarer Herzkrankheit. Med Klin 1996;91:458-65.
42. Schoebel FC, Gradaus F, Jax TW, Stiegler HM, Stein DA, Borries M, Kelm M, Strauer BE, Leschke M. Die Bedeutung der Koronarthrombose für die chronische Myokardischämie. Z Kardiol 1997;86:Suppl 1:71-83.
43. Schoebel FC, Jax TW, Fischer Y, Strauer BE. Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris. Heart 1997;77:13-7.
44. Schoebel FC, Frazier OH, Jessurun GAJ, de Jongste MJL, Kadipasaoglu KA, Jax TW, Heintzen MP, Cooley DA, Strauer BE, Leschke M. Refractory angina pectoris in end-stage coronary artery disease - Evolving therapeutic concepts. Am Heart J (in press).
45. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D & The HELP-Study Group. The HELP-LDL-apharesis multicenter study, an angiographically assessed trial on the role of LDL-apharesis in the secondary prevention of coronary heart disease. II Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
46. Shub C. Stable angina pectoris: 3. Medical treatment. Mayo Clin Proc 1990;65:256-73.
47. Siegrist J, Broer M, Junge A. Profil der Lebensqualität Chronischkranker. Göttingen-Toronto: Hogrefe, 1995.
48. Smith EB, Kean A, Grant A, Stirk D. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990;10:263-75.
49. Tolins M, Weir EK, Chesler E, Pierpont GL. "Maximal" drug therapy is not necessarily optimal in chronic angina pectoris. J Amer Coll Cardiol 1984;3:1051-7.
50. Treasure CB, Klein JL, Weintraub WS, Talley J, Stillablower ME, Kosinski AS, Zhang J, Bocuzzi SJ, Cedarholm JC, Alexander W. Beneficial effect of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
51. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JD, Davis K, Killip T, Passamani E, Norris E, Morris C, Mathur V, Varanauskas E, Chalmers TC. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563-70.